Toleriane - New clinical study results

  • 4min
  • May. 2022
  • Supported by
  • La Roche-Posay

La Roche-Posay is dedicated to ensuring our products are tolerated by the most sensitive skin. That's why we organized a clinical study to evaluate skin sensitivity of subjects with a history of skin intolerance to cosmetic care. Furthermore, the soothing, repairing, and protecting effect of TOLERIANE DERMALLERGO CREAM is tested.

The clinical study, which lasted one month, included male and female subjects of the Caucasian type, over the age of 16 who presented an allergy ground and who have experienced former intolerance to their cosmetic routine.

First, cutaneous reactivity was tested. The subjects showed a significant decrease in reactivity of 39% at day 14 and 64% at day 28. TOLERIANE DERMALLERGO CREAM proved to have a soothing effect on 81% of the subjects at the end of the clinical study. 

GRAPHS ETUDES CLINIQUES CREAM-min

Moreover, TOLERIANE DERMALLERGO CREAM presented a substantial improvement of skin sensitivity after 28 days.

  • 99% of pruritus reduction
  • 100% redness reduction
  • 98% decrease of burning sensations and tingling

 After a self-assessment:

According to at least 97% of the dermatologists and subjects participating in the study, TOLERIANE DERMALLERGO CREAM shows an excellent + good tolerance. Therefore, it can be included in the daily skin care routine of subjects with sensitive to allergy-prone skin.